Ralfinamide Salt Crystallization Removing Genotoxic Impurities
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing ralfinamide methanesulfonate and its R-enantiomer often result in products contaminated with genotoxic impurities and residual solvents, posing challenges for industrial-scale production and meeting regulatory standards.
Innovation Solution
A new process involving crystallization from water or a mixture of water with acetone, or exposure to an air stream with high humidity, followed by removal of crystallization water, to produce the methanesulfonate salt in high yields and high purity, free from genotoxic impurities and residual solvents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional crystallization methods using organic solvents (isopropanol, ethyl acetate) are used, then high yields are achieved, but genotoxic impurities and residual solvents contaminate the product
Solution Approach 1:
The invention changes the fundamental parameter of crystallization solvent from organic solvents (isopropanol, ethyl acetate) to water or water/acetone mixtures. This parameter change eliminates the formation of genotoxic esters while maintaining high yields through optimized crystallization conditions including temperature control and solvent composition ratios
Solution Approach 2:
The invention converts the previously harmful water (which can form genotoxic esters with certain solvents) into a beneficial crystallization medium. By using water or water/acetone mixtures under controlled conditions, the process eliminates organic solvent residues and genotoxic impurities while achieving high yields through careful control of crystallization parameters
2Object-affected harmful factors
If strict purification to remove genotoxic impurities is implemented, then product safety is improved, but manufacturing complexity and cost increase
Solution Approach 1:
The invention performs preliminary action by selecting a crystallization solvent system (water or water/acetone) that prevents the formation of genotoxic impurities from the outset. This preventive approach eliminates the need for complex downstream purification steps, special handling procedures, and extensive testing required when using conventional organic solvent systems
Solution Approach 2:
The invention transforms the purification challenge into a simple crystallization process by using water-based solvents. The genotoxic impurities that would normally require complex removal procedures are prevented from forming in the first place, converting a potentially harmful byproduct problem into a benign crystallization process
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process achieves high enantiomeric and chemical purity, significantly reducing genotoxic impurities and residual solvents, enhancing the toxicological profile and economic viability of ralfinamide methanesulfonate production.
Implementation Method 1
crystallization from water or a mixture of water with acetone
Implementation Method 2
exposure to an air stream with high humidity
Implementation Method 3
removal of the crystallization water on heating
Data Source
AI summary
The invention relates to a new process for the production and/or purification of the salt of the compound (S)-2-[4-(2-fluorobenzyloxy) benzylamino]propanamide, i.e. ralfinamide, or the respective R-enantiomer, with methane sulfonic acid in high yields and very high enantiomeric and chemical purity in the form of the crystalline anhydrous polymorph identified as form A, wherein said salt is substantially free from impurities having genotoxic effect, such as (C1-C5)alkanylmethanesulfonates, and residual solvents known as potential precursors thereof, such as (C1-C5)alkanols or esters thereof with lower alkanoic acids.